Fibrocystic disease of the breast in premenopausal women: histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment

Article Abstract:

Chronic fibrocystic mastopathy, or fibrocystic disease of the breast, is characterized by the formation of very small fiber-like breast tumors that have degenerated into cysts, or fluid-filled sac-like structures. This condition has been associated with the development of uterine fibroid tumors. The effect of a luteinizing hormone releasing hormone analog, (/D-Trp6~-LHRH, Ipsen-Biotech, Paris) was assessed in 66 women with fibrocystic mastopathy. (An analog is a chemical or substance with similar properties; in this case, the effect is decreasing the estrogen level.) A characteristic hormonal profile was not detected in 52 percent of the patients. Fifty-seven percent of the women were found to have estrogen and/or progesterone receptors (membrane sites that specifically bind estrogen and progesterone). The levels of hormone receptors were correlated with atypical proliferative mastopathy (breast disease characterized by unusual overgrowth of cells) in 87.5 percent of cases. Breast disease was associated with the formation of fibroid (fiber-like) tumors of the uterus in 73 percent of cases. All patients were treated for three to six months with the LHRH analog /D-Trp6~-LHRH. If only a partial response (incomplete regression of breast cysts) was obtained at three months, the anti-estrogen drug tamoxifen or the progestin cyproterone acetate was added to the drug regimen. The response was complete in 29 women treated with the LHRH agonist alone, four women treated with both the LHRH analog and tamoxifen, and two women treated with the LHRH analog and cyproterone acetate. The response was partial in 30 patients. Half of the women were treated with drugs that inhibit the estrogen receptor. Patients with recurrent breast cysts were the most responsive to treatment. Although treatment response was not related to the hormone receptor status, the use of receptor-inhibiting drugs enhanced the effect of the LHRH analog. These findings show that LHRH analogs are effective in treating women with chronic breast disease, and especially those with fibroid tumors of the uterus. (Consumer Summary produced by Reliance Medical Information, Inc.)

Physiological aspects, Statistics, Hormone therapy, Fibrocystic breast disease

---

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice

Article Abstract:

Targeting chemotherapy to the receptor for luteinizing hormone-releasing hormone may reduce its toxicity when used to treat ovarian cancer. This is done by combining the chemotherapy drug with luteinizing hormone-releasing hormone, a naturally occurring hormone in the body. Some types of ovarian cancer have the receptor for luteinizing hormone-releasing hormone on their surface. The targeted chemotherapy would bind to this receptor and the toxic drug would kill the tumor. In a study of mice, the hormone was linked to a chemotherapy drug related to doxorubicin (Adriamycin). This combination inhibited tumor growth with few side effects.

Innovations, Chemotherapy, Gonadotropin releasing hormone, Gonadorelin

---

Internalization of cytotoxic anolog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system

Article Abstract:

The mechanism of action of AN-152 in ovarian and endometrial cancer cells in vitro was studied. It was found that the efficacy of AN-152 is inversely correlated with carboxylesterase activity and it was more effective than doxorubicin at equimolar concentrations.

United States, Product information, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Anticancer Drugs, Chemotherapeutic Drugs, Care and treatment, Testing, Drug therapy, Antineoplastic agents, Endometrial cancer, Antimitotic agents

Similar abstracts:

• Abstracts: Comparison of the pharmacology of nafarelin and danazol. Gonadotropin-releasing hormone analogs in the treatment of endometriomas
• Abstracts: Gastroduodenal mucosa in uraemia: endoscopic and histological correlation and prevalence of helicobacter-like organisms
• Abstracts: Human oocyte and preembryo donation: an evolving method for the treatment of infertility
• Abstracts: Reflections of the self: atypical misidentification and delusional syndromes in two patients with Alzheimer's disease
• Abstracts: Effects of shellfish consumption on lipoproteins in normolipidemic men

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.